

Doctor's Order Sheet FOLFOX 85 Avastin® (bevacizumab) Regimen:

OXALIplatin 85 - leucovorin 400 - fluorouracil 400 - fluorouracil

Date of Birth:

Name

HCN

2400 - Avastin® (bevacizumab) 5 mg/kg (Part I)

ARIA Protocol Name: FOLFOX 85 Avastin (bevacizumab) 14D Adult Chemotherapy- Medical Oncology

Metastatic Colorectal Carcinoma



CC1470 0018 09 2020

| Aller | gies: | | | | | ☐ No Known | | | | |
|---------------|--|------------------------|---------|--|--------------|-----------------|--|--|--|--|
| | DD/MONTH/YYYY of | Cycle Duration: 14 day | | anned Administration Date of previous cycle: | | | | | | |
| MAY P | ROCEED WITH DOS | ES AS WRITTEN IF: | | | | | | | | |
| • | • ANC greater than or equal to 1.2 X 109/L and platelets greater than or equal to 75 X 109/L, otherwise notify | | | | | | | | | |
| | Medical Oncologist | | | | | | | | | |
| • | BP less than or equal to 160/100mmHg, otherwise notify Medical Oncologist | | | | | | | | | |
| • | LFT's and Bilirubin assessed | | | | | | | | | |
| • | Dipstick Urine or laboratory urinalysis for protein at the beginning of each odd (1, 3, 5) | | | | | | | | | |
| | numbered cycle. If results are 2+ or 3+ or greater than or equal to 1 g/L laboratory urinalysis | | | | | | | | | |
| | for protein, collect 24-hour urine for total protein within 3 days before the next cycle. | | | | | | | | | |
| | If this result is abnormal, dose reductions are required. | | | | | | | | | |
| PREM | EDICATIONS (FOR H | OSPITAL PHARMACY): | | | | | | | | |
| □ ond | ansetron 8 mg PO or | n day 1 | | | | | | | | |
| □ dex | amethasone 8 mg PC | on day 1 | | | | | | | | |
| □ Oth | er: | | | | | | | | | |
| L PLEAS | E REFER TO CHEMO | THERAPY LETTER WHEN | ORDER | ING SUPPORTIVE MEI | DICATIONS FO | OR THIS PATIENT | | | | |
| | | | | | | | | | | |
| Authori | zed Prescriber: | | Date: _ | DD/MON I H/YYYY | Time: | | | | | |
| Authori | zed Prescriber's Signa | ature: | | ID #: | | | | | | |
| Nurse's Name: | | | te: | DD/MONTH/YYYY | Time: | | | | | |
| Nurse's | Signature: | | | | | | | | | |

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Page 1 of 2 CP-0018 2020/09



Nurse's Signature:

Doctor's Order Sheet FOLFOX 85 Avastin® (bevacizumab)

Regimen:

OXALIPlatin 85 - leucovorin 400 - Date of fluorouracil 400 - fluorouracil

Name

HCN

2400 - Avastin® (bevacizumab) 5 mg/kg (Part II)

ARIA Protocol Name: FOLFOX 85 Avastin (bevacizumab) 14D Adult Chemotherapy - Medical Oncology

Metastatic Colorectal Carcinoma



| Weight:kg Height: | cm | Body Surface Area | (BSA) = | | | | | | | | | |
|---|---|-------------------|---------|--|--|--|--|--|--|--|--|--|
| CHEMOTHERAPY (FOR HOSPITAL PHARM) | ACY): | | | | | | | | | | | |
| □ OXALIplatin 85 mg/m² X BSA = | _ mg | | | | | | | | | | | |
| ☐ Dose modification: OXALIplatin 85 mg | g/m² X BSA | % = | mg | | | | | | | | | |
| IV in 500 mL D5W over 120 minutes on d | ay 1 | | | | | | | | | | | |
| □ leucovorin 400 mg/m² X BSA= | mg | | | | | | | | | | | |
| IV in 250 mL D5W over 120 minutes on d | ay 1 | | | | | | | | | | | |
| □ fluorouracil 400 mg/m² X BSA= | mg | | | | | | | | | | | |
| ☐ Dose modification: fluorouracil 400 m | ig/m² X BSA | % = | mg | | | | | | | | | |
| IV push on day 1 | | | | | | | | | | | | |
| □ fluorouracil 2400 mg/m² X BSA= | mg | | | | | | | | | | | |
| □ Dose modification: fluorouracil 2400 mg/m² X BSA% =mg | | | | | | | | | | | | |
| IV in D5W over 46 hours | | | | | | | | | | | | |
| □ Avastin® (bevacizumab) 5 mg/kg X weight (kg) = mg | | | | | | | | | | | | |
| IV in 100 mL normal saline over 10 minu | tes | | | | | | | | | | | |
| PLEASE REFER TO CHEMOTHERAPY LETTE | D5W over 46 hours (bevacizumab) 5 mg/kg X weight (kg) = mg | | | | | | | | | | | |
| Authorized Prescriber: | Date: | DD/MONTH/YYYY | Time: | | | | | | | | | |
| Authorized Prescriber's Signature: | | ID #: | | | | | | | | | | |
| Nurse's Name: | Date: | DD/MONTH/YYYY | Time: | | | | | | | | | |

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Page 2 of 2 CP-0018 2020/09